Lannett Company Inc
Change company Symbol lookup
Select an option...
LCI Lannett Company Inc
KO Coca-Cola Co
BAC Bank of America Corp
HXL Hexcel Corp
RDHL Redhill Biopharma Ltd
WASH Washington Trust Bancorp Inc
ADC Agree Realty Corp
FB Facebook Inc
HSTM HealthStream Inc

Health Care : Pharmaceuticals | Small Cap ValueCompany profile

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.


Last Trade
0.21 (3.10%)
B/A Size

Market Hours

Closing Price
Day's Change
-1.64 (-19.48%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:



5 providers
July 08, 2019
Lannett Enters Into Distribution Agreement For Levothyroxine

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a future exclusive supply and distribution agreement for the approved Levothyroxine Sodium Tablets USP of Cediprof, Inc., a wholly owned subsidiary of privately held...(PR Newswire)

July 03, 2019
FDA Clears Path For The Continuing Review Of Lannett Company's New Drug Application

Lannett Company, Inc. (NYSE: LCI) today commented on the U.S. Food and Drug Administration's (FDA) denial of a Citizen Petition submitted by Genus Lifesciences requesting that the FDA refuse to accept any submissions related to Lannett's 505(b)(2)...(PR Newswire)

June 28, 2019
Lannett Enters Into Distribution Agreement For Dantrolene Capsules, Commences Product Launch

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a three-year agreement with Elite Pharmaceuticals to be the exclusive U.S. distributor of a Dantrolene Capsules 25 mg, 50 mg and 100 mg. Total U.S. sales of Dantrolene...(PR Newswire)

June 18, 2019
Lannett Launches Aspirin And Extended-Release Dipyridamole Capsules

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to the reference listed drug, Aggrenox(R) Capsules, 25 mg/200 mg, of...(PR Newswire)

June 12, 2019
Lannett To Participate At Two Investor Conferences In June

Lannett Company, Inc. (NYSE: LCI) today announced its participation at two upcoming investor conferences. Schedule below: -- Raymond James 2019 Life Sciences and MedTech Conference, at 11:30 a.m. ET, Wednesday, June 19, 2019 at the Lotte New York...(PR Newswire)

June 05, 2019
Lannett Announces Initiation Of Human Clinical Trial Of Biosimilar Insulin Glargine Versus Us Lantus(R)

Lannett Company, Inc. (NYSE: LCI) today announced the commencement of a human clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC). The...(PR Newswire)

May 30, 2019
Lifshitz & Miller LLP Announces Investigation of A.O. Smith Corporation, Cray Inc., electroCore, Inc., Fred's Inc., Intersect ENT, Inc., Jumia Technologies AG, Lannett Company Inc., and Zayo Group Holdings, Inc.

A.O. Smith Corporation (AOS) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations questioning AOS' access to $359 million in China. If you are an AOS investor, and would like...(PR Newswire)

May 29, 2019
Lannett Commences Marketing Generic Concerta(R)

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 mg, 27 mg, 36 mg and 54 mg strengths, an AB-rated generic equivalent to the brand...(PR Newswire)

May 24, 2019
Lannett Announces CFO Retirement

Lannett Company, Inc. (NYSE: LCI) today announced that the company's chief financial officer (CFO), Martin Galvan, 67, will retire on August 30, 2019, following the planned submission of the company's Form 10-K for fiscal year 2019. Galvan will...(PR Newswire)

May 23, 2019
(LCI) Alert: Johnson Fistel, LLP Announces Investigation of Lannett Company, Inc.; Long Term Investors Encouraged to Contact Firm

Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by Lannett Company, Inc. (NYSE: LCI) ("Lannett") and certain of its officers. In 2017 a securities class action lawsuit was filed on...(PR Newswire)

Scott+Scott Attorneys at Law LLP is Investigating Claims on Behalf of Shareholders of Lannett Company, Inc. (LCI)

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating whether certain directors and officers of Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI) breached their...(PR Newswire)

Lannett Appoints Melissa V. Rewolinski, PhD, To Board Of Directors

Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Melissa V. Rewolinski, PhD, to its board of directors, effective July 1, 2019. Following the appointment of Dr. Rewolinski, the board will comprise eight directors. (PR Newswire)

May 21, 2019
Haeggquist & Eck Investigates Conspiracy to Fix Prices on Generic Drugs by Lannett Officers and Directors

Haeggquist & Eck, LLP, a leading shareholder rights litigation firm, is investigating whether certain officers and directors of Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI) breached their fiduciary...(BusinessWire)

Lannett Purchases Additional $30.5 Million Of Term A Loans

Lannett Company, Inc. (NYSE: LCI) today announced that it completed the purchase of approximately $30.5 million, face value, of its Term A Loans in a private transaction. (PR Newswire)

May 17, 2019
Robbins Arroyo LLP: Shareholder Class Action Against Lannett Company (LCI) Survives Motion to Dismiss

Shareholder rights law firm Robbins Arroyo LLP announces that Lannett Company (NYSE: LCI) may face damages caused by a pending securities lawsuit action lawsuit. Lannett develops, manufactures, packages, markets, and distributes...(BusinessWire)

May 16, 2019
Bragar Eagel & Squire, P.C. is Investigating Lannett Company, Inc. (NYSE: LCI) on Behalf of Lannett Stockholders and Encourages Lannett Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against Lannett Company, Inc. (NYSE: LCI) on behalf of Lannett stockholders. Our investigation concerns whether Lannett has violated the federal securities laws and/or engaged in...(Globe Newswire)

Lannett Begins Marketing Generic Adderall(R)

Lannett Company, Inc. (NYSE: LCI) today announced that it has begun marketing a generic version of Adderall(R), an immediate-release (IR) mixed salt of a single entity Amphetamine tablet product (Dextroamphetamine Saccharate, Amphetamine Aspartate...(PR Newswire)

May 07, 2019
SHAREHOLDER ALERT: Investigation of Lannett Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC is investigating whether certain statements made by Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI) complied with federal securities laws.On May 7, 2019, Lannett filed a Form 10-Q stating...(BusinessWire)

Lannett Company Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

Block & Leviton LLP (, a national securities litigation firm, is investigating whether Lannett Company Inc. ("Lannett" or the "Company") (NYSE: LCI) and certain of its officers and directors violated federal securities laws. (Globe Newswire)

May 06, 2019
Lannett Announces Fiscal 2019 Third-Quarter Financial Results; Raises Guidance For Fiscal 2019

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 third quarter ended March 31, 2019. "Our solid third quarter financial results reflect continued growth of our core business," said Tim Crew, chief executive...(PR Newswire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.